Načítá se...
Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma
Organ transplant recipients (OTRs) on cyclosporine A (CSA) are prone to catastrophic cutaneous squamous cell carcinoma (SCC). Allograft-sparing, cancer-targeting systemic treatments are unavailable. We have shown increased risk for catastrophic SCC in OTRs via CSA-mediated induction of IL-22. Herein...
Uloženo v:
| Vydáno v: | JCI Insight |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6171807/ https://ncbi.nlm.nih.gov/pubmed/30185657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.120750 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|